Key Takeaways
- • Coherence Neuro raised $45 million in Series A funding, co-led by Founders Fund and the OpenAI Startup Fund.
- • The company is developing implantable neurotechnology devices designed to monitor and potentially treat cancer.
- • New investors in the round include Lux Capital, 8VC, Timeless, Olive Capital and Ahren.
- • Returning backers include Blackbird, Possible Ventures, Topology Ventures, Artesian, XEIA Venture Partners, Xtal and Divergent.
Summary
Coherence Neuro, a San Francisco-based neurotechnology company, has raised $45 million in Series A funding, according to the company's announcement as reported in the primary source. The round was co-led by Founders Fund and the OpenAI Startup Fund.
The company is developing implantable devices intended to monitor and potentially treat cancer. The primary source describes the technology at a high level and does not disclose further details on clinical stage, regulatory status or valuation.
The round drew a mix of new and existing investors. New participants include Lux Capital, 8VC, Timeless, Olive Capital and Ahren. Returning backers include Blackbird, Possible Ventures, Topology Ventures, Artesian, XEIA Venture Partners, Xtal and Divergent, signaling continued confidence from earlier-stage supporters ahead of this financing.
The company is developing implantable devices intended to monitor and potentially treat cancer. The primary source describes the technology at a high level and does not disclose further details on clinical stage, regulatory status or valuation.
The round drew a mix of new and existing investors. New participants include Lux Capital, 8VC, Timeless, Olive Capital and Ahren. Returning backers include Blackbird, Possible Ventures, Topology Ventures, Artesian, XEIA Venture Partners, Xtal and Divergent, signaling continued confidence from earlier-stage supporters ahead of this financing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.